Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR4A2 | P43354 | 1/20 | 0.34 |
| ▸ | GRM5 | P41594 | 2/20 | 0.32 |
| ▸ | PLK1 | P53350 | 1/20 | 0.31 |
| ▸ | ESR1 | P03372 | 1/20 | 0.31 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.31 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.30 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.30 |
| ▸ | JAK2 | O60674 | 1/20 | 0.30 |
| ▸ | JAK3 | P52333 | 1/20 | 0.30 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19402115 | 1.00 | NR4A2 (0.34) | NR4A2GRM5PLK1ESR1HRH3 | |
| SCHEMBL20685774 | 0.81 | MAPK14 (0.42) | NR4A2GRM5PLK1ESR1MAPK14 | |
| SCHEMBL1774897 | 0.79 | GAA (0.42) | NR4A2GRM5ESR1MAPK14 | |
| SCHEMBL21550282 | 0.78 | ESR1 (0.35) | NR4A2GRM5PLK1ESR1MAPK14 | |
| SCHEMBL19402118 | 0.76 | CFD (0.33) | NR4A2GRM5PLK1ESR1HRH3 | |
| SCHEMBL20991790 | 0.76 | CFD (0.33) | NR4A2GRM5PLK1ESR1HRH3 | |
| SCHEMBL5756104 | 0.76 | GRM5 (0.36) | GRM5ESR1MAPK14JAK2JAK3 | |
| SCHEMBL20956373 | 0.75 | CCR4 (0.36) | GRM5ESR1HRH3 | |
| SCHEMBL20910766 | 0.75 | PLK1 (0.34) | NR4A2PLK1ESR1MAPK14AAK1 | |
| SCHEMBL20677070 | 0.75 | CFD (0.40) | GRM5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10682352-B2 | Compound having mutant IDH inhibitory activity, preparation method and use thereof | SHANGHAI HAIHE PHARMACEUTICAL CO., LTD. (CN) | 2020-06-16 | — | — | US | disclosed |
| US-20190111056-A1 | COMPOUND HAVING MUTANT IDH INHIBITORY ACTIVITY, PREPARATION METHOD AND USE THEREOF | SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES (CN) | 2019-04-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190111056-A1 | COMPOUND HAVING MUTANT IDH INHIBITORY ACTIVITY, PREPARATION METHOD AND USE THEREOF | IDH1, IDH3A, IDH2 | NR4A2 2888/4885GRM5 773/4885PLK1 3851/4885 |
| US-10682352-B2 | Compound having mutant IDH inhibitory activity, preparation method and use thereof | IDH1, IDH3A, IDH2 | NR4A2 2888/4885GRM5 773/4885PLK1 3851/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.